Editorial
Open access
Does gadolinium truly enhance the active surveillance of men with prostate cancer?
Medicine
Abstract
This study supports bpMRI for men stably on AS who already have an mpMRI, in programmes that biopsy every PI-RADS ≥ 3 lesion: not the diagnostic scan and not a programme that watches PI-RADS 3 lesions rather than sampling them. Settling the remainder needs a prospective surveillance cohort with paired same-visit reads and lesion-level scoring on a protocol that does not switch modality mid-way. Within those limits, gadolinium enhances the image, not the surveillance.